Ajanta Pharma Limited Total Liabilities
Ajanta Pharma Limited total liabilities. Based on the latest financial reports, Ajanta Pharma Limited (AJANTPHARM) has total liabilities worth Rs13.57 Billion INR (≈ $146.80 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Ajanta Pharma Limited liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ajanta Pharma Limited (2005–2025)
Total liabilities of Ajanta Pharma Limited from 2005 to 2025. This chart illustrates how Ajanta Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Ajanta Pharma Limited to see how much of total assets are deployed in long-term investments.
Ajanta Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Ajanta Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Poonawalla Fincorp Limited
NSE:POONAWALLA
|
India | Rs-103.48 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $194.22 Million |
|
QuantumCTek Co Ltd
SHG:688027
|
China | CN¥344.40 Million |
|
Scholar Rock Holding Corp
NASDAQ:SRRK
|
USA | $166.72 Million |
|
TaTaTu SpA
PA:ALTTU
|
France | €48.74 Million |
|
BILFINGER SE UNSP.ADR 1/5
F:GBFU
|
Germany | €2.16 Billion |
|
Camtek Ltd
TA:CAMT
|
Israel | ILA619.37 Million |
|
AVIC Capital Co Ltd
SHG:600705
|
China | CN¥376.59 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Ajanta Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AJANTPHARM current and non-current assets.
Liquidity & Leverage Metrics
Ajanta Pharma Limited Total Liabilities Ratios Explained
Ajanta Pharma Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.00 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ajanta Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ajanta Pharma Limited (2005–2025)
The table below shows the annual total liabilities of Ajanta Pharma Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs12.25 Billion ≈ $132.44 Million |
+14.34% |
| 2024-03-31 | Rs10.71 Billion ≈ $115.83 Million |
-17.04% |
| 2023-03-31 | Rs12.91 Billion ≈ $139.62 Million |
+63.17% |
| 2022-03-31 | Rs7.91 Billion ≈ $85.57 Million |
+1.04% |
| 2021-03-31 | Rs7.83 Billion ≈ $84.69 Million |
+8.79% |
| 2020-03-31 | Rs7.20 Billion ≈ $77.85 Million |
+59.62% |
| 2019-03-31 | Rs4.51 Billion ≈ $48.77 Million |
+10.74% |
| 2018-03-31 | Rs4.07 Billion ≈ $44.04 Million |
+59.68% |
| 2017-03-31 | Rs2.55 Billion ≈ $27.58 Million |
-17.57% |
| 2016-03-31 | Rs3.09 Billion ≈ $33.46 Million |
+1.35% |
| 2015-03-31 | Rs3.05 Billion ≈ $33.01 Million |
-14.26% |
| 2014-03-31 | Rs3.56 Billion ≈ $38.50 Million |
+9.51% |
| 2013-03-31 | Rs3.25 Billion ≈ $35.16 Million |
-7.32% |
| 2012-03-31 | Rs3.51 Billion ≈ $37.94 Million |
+19.58% |
| 2011-03-31 | Rs2.93 Billion ≈ $31.72 Million |
-5.43% |
| 2010-03-31 | Rs3.10 Billion ≈ $33.54 Million |
+1.44% |
| 2009-03-31 | Rs3.06 Billion ≈ $33.07 Million |
+36.04% |
| 2008-03-31 | Rs2.25 Billion ≈ $24.31 Million |
+47.15% |
| 2007-03-31 | Rs1.53 Billion ≈ $16.52 Million |
+15.49% |
| 2006-03-31 | Rs1.32 Billion ≈ $14.30 Million |
+11.06% |
| 2005-03-31 | Rs1.19 Billion ≈ $12.88 Million |
-- |
About Ajanta Pharma Limited
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic a… Read more